Financhill
Sell
24

BIOLQ Quote, Financials, Valuation and Earnings

Last price:
$0.0100
Seasonality move :
-2.7%
Day range:
$0.0090 - $0.0103
52-week range:
$0.0040 - $0.2570
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.00x
P/B ratio:
--
Volume:
71.3K
Avg. volume:
100.3K
1-year change:
-93.48%
Market cap:
$329.4K
Revenue:
$49.2M
EPS (TTM):
-$2.04

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BIOLQ
Biolase
$13.5M -$0.01 3.78% -99.71% $1.2000
ALGN
Align Technology
$999.2M $2.45 -1.71% 44.8% $254.64
MLSS
Milestone Scientific
$2.7M -$0.01 17.38% -66.67% --
NVST
Envista Holdings
$645.9M $0.22 -2.29% 51.15% $21.33
SONX
Sonendo
-- -- -- -- --
XRAY
Dentsply Sirona
$920.3M $0.43 -10.43% 232.77% $20.20
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BIOLQ
Biolase
$0.0090 $1.2000 $329.4K -- $0.00 0% 0.00x
ALGN
Align Technology
$160.51 $254.64 $11.8B 28.61x $0.00 0% 3.01x
MLSS
Milestone Scientific
$0.92 -- $71.7M -- $0.00 0% 8.13x
NVST
Envista Holdings
$16.25 $21.33 $2.8B -- $0.00 0% 1.12x
SONX
Sonendo
-- -- -- -- $0.00 0% --
XRAY
Dentsply Sirona
$15.33 $20.20 $3.1B -- $0.16 4.18% 0.82x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BIOLQ
Biolase
142.17% 1.859 714.45% 0.23x
ALGN
Align Technology
-- 2.453 -- 1.02x
MLSS
Milestone Scientific
-- 2.706 -- 1.42x
NVST
Envista Holdings
32.21% 1.056 41.98% 1.63x
SONX
Sonendo
-- 0.000 -- --
XRAY
Dentsply Sirona
52.37% 0.344 56.57% 0.55x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BIOLQ
Biolase
$4.4M -$695K -129.74% -21668.17% -7.48% -$4.5M
ALGN
Align Technology
$696.9M $177.1M 11.12% 11.12% 17.79% $263.1M
MLSS
Milestone Scientific
$1.8M -$1.5M -61.33% -61.33% -58.44% -$973.9K
NVST
Envista Holdings
$372.5M $67.7M -22.7% -32.33% 7.11% $123.8M
SONX
Sonendo
-- -- -- -- -- --
XRAY
Dentsply Sirona
$446M $9M -18.42% -32.39% -56.02% $36M

Biolase vs. Competitors

  • Which has Higher Returns BIOLQ or ALGN?

    Align Technology has a net margin of -13.16% compared to Biolase's net margin of 10.43%. Biolase's return on equity of -21668.17% beat Align Technology's return on equity of 11.12%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIOLQ
    Biolase
    40.39% -$0.04 $12.4M
    ALGN
    Align Technology
    70.03% $1.39 $3.9B
  • What do Analysts Say About BIOLQ or ALGN?

    Biolase has a consensus price target of $1.2000, signalling upside risk potential of 22122.22%. On the other hand Align Technology has an analysts' consensus of $254.64 which suggests that it could grow by 58.64%. Given that Biolase has higher upside potential than Align Technology, analysts believe Biolase is more attractive than Align Technology.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIOLQ
    Biolase
    1 1 0
    ALGN
    Align Technology
    9 5 0
  • Is BIOLQ or ALGN More Risky?

    Biolase has a beta of 0.817, which suggesting that the stock is 18.311% less volatile than S&P 500. In comparison Align Technology has a beta of 1.687, suggesting its more volatile than the S&P 500 by 68.738%.

  • Which is a Better Dividend Stock BIOLQ or ALGN?

    Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Align Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biolase pays -- of its earnings as a dividend. Align Technology pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIOLQ or ALGN?

    Biolase quarterly revenues are $10.9M, which are smaller than Align Technology quarterly revenues of $995.2M. Biolase's net income of -$1.4M is lower than Align Technology's net income of $103.8M. Notably, Biolase's price-to-earnings ratio is -- while Align Technology's PE ratio is 28.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.00x versus 3.01x for Align Technology. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIOLQ
    Biolase
    0.00x -- $10.9M -$1.4M
    ALGN
    Align Technology
    3.01x 28.61x $995.2M $103.8M
  • Which has Higher Returns BIOLQ or MLSS?

    Milestone Scientific has a net margin of -13.16% compared to Biolase's net margin of -58.13%. Biolase's return on equity of -21668.17% beat Milestone Scientific's return on equity of -61.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIOLQ
    Biolase
    40.39% -$0.04 $12.4M
    MLSS
    Milestone Scientific
    73.05% -$0.02 $7.2M
  • What do Analysts Say About BIOLQ or MLSS?

    Biolase has a consensus price target of $1.2000, signalling upside risk potential of 22122.22%. On the other hand Milestone Scientific has an analysts' consensus of -- which suggests that it could grow by 131%. Given that Biolase has higher upside potential than Milestone Scientific, analysts believe Biolase is more attractive than Milestone Scientific.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIOLQ
    Biolase
    1 1 0
    MLSS
    Milestone Scientific
    0 0 0
  • Is BIOLQ or MLSS More Risky?

    Biolase has a beta of 0.817, which suggesting that the stock is 18.311% less volatile than S&P 500. In comparison Milestone Scientific has a beta of 1.409, suggesting its more volatile than the S&P 500 by 40.929%.

  • Which is a Better Dividend Stock BIOLQ or MLSS?

    Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Milestone Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biolase pays -- of its earnings as a dividend. Milestone Scientific pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIOLQ or MLSS?

    Biolase quarterly revenues are $10.9M, which are larger than Milestone Scientific quarterly revenues of $2.5M. Biolase's net income of -$1.4M is higher than Milestone Scientific's net income of -$1.5M. Notably, Biolase's price-to-earnings ratio is -- while Milestone Scientific's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.00x versus 8.13x for Milestone Scientific. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIOLQ
    Biolase
    0.00x -- $10.9M -$1.4M
    MLSS
    Milestone Scientific
    8.13x -- $2.5M -$1.5M
  • Which has Higher Returns BIOLQ or NVST?

    Envista Holdings has a net margin of -13.16% compared to Biolase's net margin of 0.18%. Biolase's return on equity of -21668.17% beat Envista Holdings's return on equity of -32.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIOLQ
    Biolase
    40.39% -$0.04 $12.4M
    NVST
    Envista Holdings
    57.05% $0.01 $4.3B
  • What do Analysts Say About BIOLQ or NVST?

    Biolase has a consensus price target of $1.2000, signalling upside risk potential of 22122.22%. On the other hand Envista Holdings has an analysts' consensus of $21.33 which suggests that it could grow by 31.28%. Given that Biolase has higher upside potential than Envista Holdings, analysts believe Biolase is more attractive than Envista Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIOLQ
    Biolase
    1 1 0
    NVST
    Envista Holdings
    3 10 1
  • Is BIOLQ or NVST More Risky?

    Biolase has a beta of 0.817, which suggesting that the stock is 18.311% less volatile than S&P 500. In comparison Envista Holdings has a beta of 1.326, suggesting its more volatile than the S&P 500 by 32.59%.

  • Which is a Better Dividend Stock BIOLQ or NVST?

    Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Envista Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biolase pays -- of its earnings as a dividend. Envista Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIOLQ or NVST?

    Biolase quarterly revenues are $10.9M, which are smaller than Envista Holdings quarterly revenues of $652.9M. Biolase's net income of -$1.4M is lower than Envista Holdings's net income of $1.2M. Notably, Biolase's price-to-earnings ratio is -- while Envista Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.00x versus 1.12x for Envista Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIOLQ
    Biolase
    0.00x -- $10.9M -$1.4M
    NVST
    Envista Holdings
    1.12x -- $652.9M $1.2M
  • Which has Higher Returns BIOLQ or SONX?

    Sonendo has a net margin of -13.16% compared to Biolase's net margin of --. Biolase's return on equity of -21668.17% beat Sonendo's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BIOLQ
    Biolase
    40.39% -$0.04 $12.4M
    SONX
    Sonendo
    -- -- --
  • What do Analysts Say About BIOLQ or SONX?

    Biolase has a consensus price target of $1.2000, signalling upside risk potential of 22122.22%. On the other hand Sonendo has an analysts' consensus of -- which suggests that it could fall by --. Given that Biolase has higher upside potential than Sonendo, analysts believe Biolase is more attractive than Sonendo.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIOLQ
    Biolase
    1 1 0
    SONX
    Sonendo
    0 0 0
  • Is BIOLQ or SONX More Risky?

    Biolase has a beta of 0.817, which suggesting that the stock is 18.311% less volatile than S&P 500. In comparison Sonendo has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock BIOLQ or SONX?

    Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sonendo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biolase pays -- of its earnings as a dividend. Sonendo pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIOLQ or SONX?

    Biolase quarterly revenues are $10.9M, which are larger than Sonendo quarterly revenues of --. Biolase's net income of -$1.4M is higher than Sonendo's net income of --. Notably, Biolase's price-to-earnings ratio is -- while Sonendo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.00x versus -- for Sonendo. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIOLQ
    Biolase
    0.00x -- $10.9M -$1.4M
    SONX
    Sonendo
    -- -- -- --
  • Which has Higher Returns BIOLQ or XRAY?

    Dentsply Sirona has a net margin of -13.16% compared to Biolase's net margin of -47.51%. Biolase's return on equity of -21668.17% beat Dentsply Sirona's return on equity of -32.39%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIOLQ
    Biolase
    40.39% -$0.04 $12.4M
    XRAY
    Dentsply Sirona
    49.28% -$2.16 $4.1B
  • What do Analysts Say About BIOLQ or XRAY?

    Biolase has a consensus price target of $1.2000, signalling upside risk potential of 22122.22%. On the other hand Dentsply Sirona has an analysts' consensus of $20.20 which suggests that it could grow by 31.77%. Given that Biolase has higher upside potential than Dentsply Sirona, analysts believe Biolase is more attractive than Dentsply Sirona.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIOLQ
    Biolase
    1 1 0
    XRAY
    Dentsply Sirona
    2 11 0
  • Is BIOLQ or XRAY More Risky?

    Biolase has a beta of 0.817, which suggesting that the stock is 18.311% less volatile than S&P 500. In comparison Dentsply Sirona has a beta of 0.976, suggesting its less volatile than the S&P 500 by 2.383%.

  • Which is a Better Dividend Stock BIOLQ or XRAY?

    Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dentsply Sirona offers a yield of 4.18% to investors and pays a quarterly dividend of $0.16 per share. Biolase pays -- of its earnings as a dividend. Dentsply Sirona pays out -13.85% of its earnings as a dividend.

  • Which has Better Financial Ratios BIOLQ or XRAY?

    Biolase quarterly revenues are $10.9M, which are smaller than Dentsply Sirona quarterly revenues of $905M. Biolase's net income of -$1.4M is higher than Dentsply Sirona's net income of -$430M. Notably, Biolase's price-to-earnings ratio is -- while Dentsply Sirona's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.00x versus 0.82x for Dentsply Sirona. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIOLQ
    Biolase
    0.00x -- $10.9M -$1.4M
    XRAY
    Dentsply Sirona
    0.82x -- $905M -$430M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Is Buffett Buying and Selling Now?
What Is Buffett Buying and Selling Now?

In Q4 of last year, Warren Buffett made a few…

3 Safest Stocks to Buy Now
3 Safest Stocks to Buy Now

With the S&P 500 now in correction and stocks selling…

Tesla Stock: The Bear Case
Tesla Stock: The Bear Case

The recent stock market drop has been a punishing time…

Stock Ideas

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 39x

Sell
47
Is MSFT Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 32x

Alerts

Sell
5
CABO alert for Mar 14

Cable One [CABO] is down 3.97% over the past day.

Sell
38
ADBE alert for Mar 14

Adobe [ADBE] is up 4.43% over the past day.

Sell
29
CAR alert for Mar 14

Avis Budget Group [CAR] is up 11.68% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock